Clinical trial
A Study of An Approved Vaccine at Mumps Expiry Potency in Healthy Children 12 to…
NCT00092391 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00092391 |
|---|---|
| Title | A Study of An Approved Vaccine at Mumps Expiry Potency in Healthy Children 12 to 18 Months of Age (V205C-007)(COMPLETED) |
| Official title | A Study of M-M-R(TM) II at Mumps Expiry Potency in Healthy Children 12 to 18 Months of Age |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Measles, Mumps, Rubella, Varicella |
| Intervention type | Biological |
| Interventions | Comparator: M-M-R(TM) II, measles, mumps, and rubella virus vaccine live, Comparator: VARIVAX(TM) Varicella Virus Vaccine Live (Oka-Merck) |
| Enrollment | 1,997 |
| Start date | Feb 1, 1999 |
| Primary completion | Jul 1, 2001 |
| Completion | Jul 1, 2001 |
| First posted | Sep 27, 2004 |
| Last update posted | Oct 23, 2015 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: